HOME >> MEDICINE >> NEWS
St. Jude leukemia therapy overcomes differences in treatment outcome between black, white children

(MEMPHIS, TENN.--October 14, 2003) Investigators at St. Jude Children's Research Hospital have found that black children are equally likely as white children to benefit from improved treatment for acute lymphoblastic leukemia (ALL), if given equal access to the most advanced therapies.

This finding--that black and white children had virtually equal rates of survival over 10 years--contrasts with the results of clinical studies from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). The POG and CCG multi-center studies showed that black children lagged behind white children in the cure rate for ALL.

Even though black children referred to St. Jude were more likely to have high-risk leukemia and be socioeconomically underprivileged, they enjoyed the same excellent treatment results as white children, according to Ching-Hon Pui, M.D., director of the St. Jude Leukemia/Lymphoma division.

Pui is senior author of this study, which appears in the Oct. 15 issue of the Journal of the American Medical Association. Despite black children presenting with more bulky disease at diagnosis and having unfavorable genetic subtypes of leukemia, the St. Jude treatment was able to achieve high cure rates that were equal in black and white children.

"It's remarkable that, although African-American children with ALL are more likely than white children to have high-risk leukemia, the black children in our studies derived as much benefit from therapy as white children," said William Evans, Pharm.D., St. Jude scientific director and a co-author of the study. "This is apparently due to the modifications we made to our previous, very successful therapies for ALL, making those treatments even more effective."

One factor contributing to the treatment success rate among black children is that all St. Jude patients received a personally tailored approached to treatment--called risk-directed therapy--regardless of health insurance s
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
14-Oct-2003


Page: 1 2

Related medicine news :

1. Both inherited traits and tumor mutations affect response to treatment of leukemia
2. Plant derivative attacks the roots of leukemia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
5. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
6. New leukemia drug shows promise in overriding all Gleevec resistance
7. Cord blood transplantation now a viable option for adult leukemia patients
8. Peptide vaccine can produce complete remission in myeloid leukemia patients
9. Methylphenidate improves attention, behavior of children surviving leukemia, brain tumors
10. Obesity linked to another cancer - leukemia in older women
11. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... St. Petersburg, Fla. (PRWEB) , ... April 29, ... ... All Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia ... 3,000 babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology:
Cached News: